Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
HemaSphere · 2024-08 · 8 (8)
DOI: 10.1002/hem3.130 ↗At a glance
Übersichtsarbeit in HemaSphere, published online on 2024-08-22. Written by Inna Y Gong and 4 co-authors. Institution: Princess Margaret Cancer Center Toronto Ontario Canada. Cited 10 times so far (Crossref); 140 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
CD19‐directed autologous chimeric antigen receptor T cell (CAR‐T) therapy has transformed the management of relapsed/refractory (R/R) large B cell lymphoma (LBCL). Initially approved in the third line and beyond setting, CAR‐T is now standard of care (SOC) for second‐line treatment in patients with refractory disease or early relapse (progression within 12 months) following primary chemoimmunotherapy. Despite becoming SOC, most patients do not achieve complete response, and long‐term cure is only observed in approximately 40% of patients. Accordingly, there is an urgent need to better understand the mechanisms of treatment failure and to identify patients that are unlikely to benefit from SOC CAR‐T. The field needs robust biomarkers to predict treatment outcome, as better understanding of prognostic factors and mechanisms of resistance can inform on the design of novel treatment approaches for patients predicted to respond poorly to SOC CAR‐T. This review aims to provide a comprehensive overview of clinical, molecular, imaging, and cellular features that have been shown to influence outcomes of CAR‐T therapy in patients with R/R LBCL.
Authors and institutions
- Princess Margaret Cancer Center Toronto Ontario Canada.
- Division of Medical Oncology and Hematology University Health Network Toronto Ontario Canada.
- Department of Immunology University of Toronto Toronto Ontario Canada.
ORCID profiles: Inna Y Gong
Cite
APA
Gong, I. Y., Tran, D., Saibil, S., Laister, R. C., & Kuruvilla, J. (2024). Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma. HemaSphere, 8(8). https://doi.org/10.1002/hem3.130
Vancouver
Gong IY, Tran D, Saibil S, Laister RC, Kuruvilla J. Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma. HemaSphere. 2024;8(8). doi:10.1002/hem3.130
BibTeX
@article{Gong2024,
author = {Gong, Inna Y and Tran, Daisy and Saibil, Samuel and Laister, Rob C and Kuruvilla, John},
title = {Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma},
journal = {HemaSphere},
year = {2024},
volume = {8},
number = {8},
doi = {10.1002/hem3.130}
}
EUVIMED